The mydriasis treatment market has witnessed significant growth due to the increasing geriatric population suffering from eye disorders such as glaucoma, diabetic retinopathy, and age-related macular degeneration. Mydriasis helps in pupil dilation and provides better visibility to examine the interior parts of the eye. Drugs such as tropicamide, atropine, and phenylephrine are commonly used for mydriasis during eye tests and surgeries.
The mydriasis treatment market is estimated to be valued at USD 633.3 Mn in 2024 and is expected to reach USD 878 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.
Key players operating in the mydriasis treatment market are Bausch & Lomb, Abbott, Johnson & Johnson Vision, and Novartis AG. These companies offer a variety of eyedrops to temporarily dilate pupils for routine eye examinations, laser treatments, and retinal photography.
Growing awareness about regular eye check-ups and the increasing frequency of diagnostic procedures are boosting the demand for Mydriasis Treatment Market. Moreover, the rapidly aging global population is leading to a rise in age-related eye conditions, propelling market growth.
Get more insights on: Mydriasis Treatment Market